Session: FP17-Diabetes: New Diagnostic & Treatment Modalities
Room 307 (Moscone Center)
Poster Board SUN-807
Patients with T2DM were consecutively recruited from the Chicago community. All the participants underwent overnight polysomnography. The presence of OSA was defined by an apnea-hypopnea index (AHI) >5 events/hour. Hypopnea was defined as a 50% reduction of airflow for at least 10 seconds on a semiquantitative signal that was associated with either a 3% or greater oxygen desaturation or a cortical microarousal on the electroencephalography. The severity of OSA was graded according to commonly used clinical cutoffs as follows: no OSA (AHI < 5); mild OSA (5 < AHI < 15); moderate OSA (15 < AHI < 30); and severe OSA (AHI > 30).
A total of 115 subjects were studied: 50 men and 65 women. No sex difference was observed for age (mean ± SD; men: 56.2 ± 10.1 years; women: 54.3 ± 9.5 years), HbA1c levels (men: 7.3% ± 1.7; women: 7.4% ± 1.7), number of antidiabetic medications, insulin use, years of diabetes, and exercise levels. Compared to men, women had a higher body mass index (BMI) (men: 33.0 ± 7.1 kg/m2; women: 35.7 ± 7.5 kg/m2; p = 0.035) and were at higher risk for T2DM based on ethnicity (men: 46%; women: 77%; p < 0.01).
Out of the total of 115 patients, 98 had OSA (AHI >5), thus the overall OSA prevalence was 85%. Even after controlling for BMI and ethnicity, there was no sex difference in OSA prevalence, with 88% of men and 83% of women having OSA, respectively. When comparing men and women with OSA, there was a trend for lower severity of disease in women (mild OSA: men 23%, female 38%; moderate OSA: men 32%, female 35%; severe OSA: men 45%, female 26%; p = 0.09).
In conclusion, our study confirms that the prevalence of OSA, a well-documented risk factor for insulin resistance and cardiovascular disease, is exceptionally high in T2DM and indicates that the sex disparity in OSA prevalence that is found in non-diabetic populations is no longer present in obese subjects with T2DM. This observation suggests that OSA may be on the causal pathway leading to T2DM development.
Nothing to Disclose: GB, DG, ET, VA, HW, DAE, EV, BM
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters